About Esperion Therapeutics, Inc. - Common Stock (ESPR)
Esperion Therapeutics is a biotechnology company focused on developing and commercializing innovative therapies for cardiovascular diseases. The company specializes in creating oral medications aimed at lowering cholesterol levels, with a particular emphasis on treating patients with elevated low-density lipoprotein cholesterol (LDL-C). Esperion's research and development efforts are centered around understanding the underlying mechanisms of heart disease and providing effective solutions that can significantly reduce cardiovascular risk. Through its commitment to scientific advancement and patient care, Esperion strives to enhance the treatment landscape for individuals with hyperlipidemia and related conditions. Read More
Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular, and hepatic and renal disease, today announced they have entered into a definitive agreement for Esperion to acquire Corstasis.
– Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion’s Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth –
ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026.
ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET.
ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Alkem has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.
ANN ARBOR, Mich., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on February 10, 2026, the Company granted 11 new employees 40,200 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.
ANN ARBOR, Mich., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Wednesday, January 14, 2025.
– Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and Limb Benefits –
ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on December 4, 2025, the Company granted three new employees (i) non-qualified stock options to purchase an aggregate of 380,000 shares of common stock, all of which were granted to John Harlow, the Company’s newly appointed Chief Commercial Officer, and (ii) 435,536 restricted stock units (RSUs), 424,536 of which were awarded to Mr. Harlow, under Esperion’s 2017 Inducement Equity Incentive Plan.
ANN ARBOR, Mich., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025, at 3:30 p.m. ET.
ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026.
– Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% Compared to Placebo –
ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 4, 2025, the Company granted 23 new employees 77,650 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.
Esperion's Q3 2025 shows strong revenue growth beating estimates, but a deeper loss led to a sharp stock sell-off. The company secured key patents and targets profitability in 2026.
